Molecular signatures that predict nodal metastasis in bladder cancer: Does the primary tumor tell tales?

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 849-852

  Mitra, Anirban P ^a   Cote, Richard J ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

gene expression profiling; neoadjuvant chemotherapy; node positive disease; transitional cell carcinoma

Indexed keywords

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER TISSUE; CYSTECTOMY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MODEL; HUMAN; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; PREDICTIVE VALUE; PRIMARY TUMOR; PROGNOSIS; THERAPY DELAY; TRANSURETHRAL RESECTION;

EID: 79959808519     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.60     Document Type: Article

References (24)

1. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817-823 (2000 (Pubitemid 30242784)
2. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001 (Pubitemid 32120143)
3. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev. Urol. 10(1), 31-43 (2008
4. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003 (Pubitemid 37025405)
5. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 178(2), 451-454 (2007 (Pubitemid 47030482)
6. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst. Rev. 2, CD005246 (2005
7. Smith SC, Baras AS, Dancik G et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol. 12(2), 137-143 (2011
8. Als AB, Dyrskjøt L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13(15 Pt 1), 4407-4414 (2007 (Pubitemid 47219707)
9. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778-789 (2006 (Pubitemid 46622045)
10. Lehmann J, Retz M, Wiemers C et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, Phase III trial (AUO-AB 05/95J. Clin. Oncol. 23(22), 4963-4974 (2005 (Pubitemid 46224002)
11. Kim WJ, Kim EJ, Kim SK et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010
12. Deserno WM, Harisinghani MG, Taupitz M et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233(2), 449-456 (2004 (Pubitemid 39423804)
13. Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H. Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin. Cancer Res. 11(10), 3773-3777 (2005 (Pubitemid 40685595)
14. Hollenbeck BK, Montie JE. Early cystectomy for clinical stage T1 bladder cancer. Nat. Clin. Pract. Urol. 1(1), 4-5 (2004 (Pubitemid 40852057)
15. Mitra AP, Almal AA, George B et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6, 159 (2006
16. Bartsch G, Mitra AP, Cote RJ. Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev. Anticancer Ther. 10(12), 1945-1954 (2010
17. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24(35), 5552-5564 (2006 (Pubitemid 46631336)
18. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 4, 251-285 (2009
19. Abdueva D, Wing MR, Schaub B, Triche TJ. Experimental comparison and evaluation of the Affymetrix exon and U133Plus2 GeneChip arrays. PLoS One 2(9), e913 (2007
20. Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J. Mol. Diagn. 12(4), 409-417 (2010
21. Mitra AP, Pagliarulo V, Yang D et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 27(24), 3929-3937 (2009
22. Birkhahn M, Mitra AP, Williams AJ et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur. Urol. 57(1), 12-20 (2010
23. Mitra AP, Bartsch CC, Cote RJ. Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev. 28(3-4), 317-326 (2009
24. Lee JK, Havaleshko DM, Cho H et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104(32), 13086-1391 (2007).